- Home
- SORA vs STTK Comparison
SORA vs STTK Comparison
Compare SORA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SORA
- STTK
- Stock Information
- Founded
- SORA 2001
- STTK 2016
- Country
- SORA Hong Kong
- STTK United States
- Employees
- SORA N/A
- STTK N/A
- Industry
- SORA Other Specialty Stores
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- SORA Industrials
- STTK Health Care
- Exchange
- SORA Nasdaq
- STTK Nasdaq
- Market Cap
- SORA 131.0M
- STTK 112.6M
- IPO Year
- SORA 2025
- STTK 2020
- Fundamental
- Price
- SORA $5.41
- STTK $2.06
- Analyst Decision
- SORA
- STTK Hold
- Analyst Count
- SORA 0
- STTK 5
- Target Price
- SORA N/A
- STTK $3.00
- AVG Volume (30 Days)
- SORA 27.5K
- STTK 384.9K
- Earning Date
- SORA 01-01-0001
- STTK 11-13-2025
- Dividend Yield
- SORA N/A
- STTK N/A
- EPS Growth
- SORA N/A
- STTK N/A
- EPS
- SORA N/A
- STTK N/A
- Revenue
- SORA $17,619,363.00
- STTK $2,997,000.00
- Revenue This Year
- SORA N/A
- STTK N/A
- Revenue Next Year
- SORA N/A
- STTK N/A
- P/E Ratio
- SORA N/A
- STTK N/A
- Revenue Growth
- SORA N/A
- STTK N/A
- 52 Week Low
- SORA $3.19
- STTK $0.69
- 52 Week High
- SORA $14.15
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- SORA N/A
- STTK 52.80
- Support Level
- SORA N/A
- STTK $1.78
- Resistance Level
- SORA N/A
- STTK $2.14
- Average True Range (ATR)
- SORA 0.00
- STTK 0.21
- MACD
- SORA 0.00
- STTK -0.03
- Stochastic Oscillator
- SORA 0.00
- STTK 39.56
About SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.